Overview: NGS Mitochondrial Epilepsy Sequencing TestIntroduction: The NGS Mitochondrial Epilepsy Sequencing Test sequences mitochondrial genes to diagnose epilepsy, causing seizures. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected mitochondrial epilepsy.
Other Names: Mitochondrial Epilepsy NGS Assay, POLG/MT-TL1 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Mitochondrial epilepsy sequencing began in the 2000s with mitochondrial disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences mitochondrial genes to diagnose epilepsy, guides treatment, and evaluates patients with seizures.
Test Parameters: 1. Mitochondrial Epilepsy Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of seizures, developmental delays, or mitochondrial epilepsy symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document seizures, developmental delays, lactic acidosis, or family history of mitochondrial disorders. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, mitochondrial epilepsy implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze mitochondrial epilepsy genes (e.g., POLG, MT-TL1). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for mitochondrial epilepsy diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm mitochondrial epilepsy, guiding anticonvulsant therapy or mitochondrial supplements. Negative results may require broader mitochondrial testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: EEG, brain MRI, or lactate levels to confirm mitochondrial epilepsy diagnosis.
Test Limitations: Not all epilepsy cases are mitochondrial; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Epilepsy Guidelines, 2023; Neurology, Rahman S, 2022.
